Pharmaceutical
Home » Anticoagulant Reversal Drugs Market

Anticoagulant Reversal Drugs Market

Anticoagulant Reversal Drugs Market By Drug Class (Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexmic Acid, Desmopressin, Idarucizumab, Andexxa) – Growth, Future Prospects And Competitive Landscape, 2018 – 2026
Report Book

Published Date: March 2019
Category: Pharmaceuticals
Report ID: 59602
Report Format: PDF
No of Pages: 190

Rating: Credence Reports

Industry Outlook

The global anticoagulant reversal drugs market is expected to grow at a compound annual growth rate (CAGR) of 15.3% during the forecast period from 2018 to 2026. Reversing the effects of anticoagulants, including novel oral anticoagulants (NOACs), vitamin K antagonists, and others, is a major concern in clinical practice, especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in the last decade have increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT).

However, this growth in anticoagulants’ usage has led to a rise in the incidence of hospital admissions and deaths due to increased bleeding due to anticoagulation. According to the Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in the U.S. alone, and close to 2,000 deaths per month were attributable to anticoagulation or factor Xa inhibitor-related bleeding. These factors have led to furious research and the development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted special status and accelerated approvals for the development and swift market entry of certain anticoagulant antidotes.

Market Synopsis

Recent Approval of the First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market

In May 2018, the U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing anticoagulation effects. Andexxa received both orphan drug status and breakthrough drug designation by the U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it grow at the fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drug market owing to the increased use of these agents during critical situations. Idarucizumab, which was approved in 2015, was the only drug that could reverse dabigatran etexilate mesylate’s anticoagulant effects.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments was calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The anticoagulant reversal drugs market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class and geography.

The market is studied in order to understand the current dynamics and future trends in the global anticoagulant reversal drug market. The study includes market size and forecasts for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rates (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year.

The key players currently engaged in the anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc., and Ferring Pharmaceuticals.

Key questions are answered in this report.

  • How will the global market for anticoagulant reversal drugs perform during the forecast period from 2018 to 2026?
  • What are the most recent trends in the anticoagulant reversal drug market, as well as the most promising opportunities for key players?
  • Who are the leading players in the global anticoagulant reversal drug market?
  • Which is the leading and fastest-growing region in the global anticoagulant reversal drug market?
  • What are the drivers and restraints governing the global anticoagulant reversal drug market?
  • What is the pipeline of anticoagulant reversal drugs on the market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global ARD Market Portraiture
2.2. Global ARD Market, by Drug Class, 2017 (US$ Mn)
2.3. Global ARD Market, by Geography, 2017 (US$ Mn)

Chapter 3. Anticoagulant Reversal Drugs (ARD): Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global ARD Market, by Key Players, 2017

Chapter 4. Global Anticoagulant Reversal Drugs (ARD) Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Prothrombin Complex Concentrates (PCC)
4.3. Vitamin K
4.4. Protamine
4.5. Tranexmic Acid
4.6. Desmopressin
4.7. Idarucizumab
4.8. Andexxa
4.9. Pipeline Analysis
4.9.1. Phase III Drugs
4.9.1.1. Octaplex
4.9.2. Phase I and II Drugs (Tabular Representation)

Chapter 5. Global Anticoagulant Reversal Drugs (ARD) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. North America ARD Market Analysis, 2016 – 2026
5.1.1. North America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.1.2. North America ARD Market, by Country, 2016 – 2026 (US$ Mn)
5.1.2.1. U.S.
5.1.2.2. Canada
5.2. Europe ARD Market Analysis, 2016 – 2026
5.2.1. Europe ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. Europe ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.2.2.1. U.K.
5.2.2.2. Germany
5.2.2.3. Rest of Europe
5.3. Asia Pacific ARD Market Analysis, 2016 – 2026
5.3.1. Asia Pacific ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Asia Pacific ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. China
5.3.2.2. Japan
5.3.2.3. Rest of Asia Pacific
5.4. Latin America ARD Market Analysis, 2016 – 2026
5.4.1. Latin America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Latin America ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East & Africa ARD Market, 2016 – 2026
5.5.1. Middle East & Africa ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Middle East & Africa ARD Market, by Region, 2016 – 2026 (US$ Mn)
5.5.2.1. GCC
5.5.2.2. Rest of Middle East & Africa

Chapter 6. Company Profiles
6.1. Boehringer Ingelheim GmbH
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Fresenius Kabi AG
6.3. Pfizer, Inc.
6.4. Bausch Health Companies, Inc.
6.5. Amneal Pharmaceuticals, Inc.
6.6. CSL Behring Limited
6.7. Octapharma AG
6.8. Portola Pharmaceuticals, Inc.
6.9. Perosphere Pharmaceuticals, Inc.
6.10. Ferring Pharmaceuticals

List of Figures

FIG 1. Anticoagulant Reversal Drugs (ARD) Market: Research Methodology
FIG 2. ARD: Market Segmentation
FIG 3. Global ARD Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global ARD Market, by Geography, 2017 (US$ Mn)
FIG 5. Attractive Investment Proposition, by Geography, 2017
FIG 6. Competitive Analysis: Global ARD Market, by Key Players, 2017
FIG 7. Global Prothrombin Complex Concentrates (PCC) for ARD Market, 2016-2026 (US$ Mn)
FIG 8. Global Vitamin K for ARD Market, 2016-2026 (US$ Mn)
FIG 9. Global Protamine for ARD Market, 2016-2026 (US$ Mn)
FIG 10. Global Tranexmic Acid for ARD Market, 2016-2026 (US$ Mn)
FIG 11. Global Desmopressin for ARD Market, 2016-2026(US$ Mn)
FIG 12. Global Idarucizumab for ARD Market, 2016-2026(US$ Mn)
FIG 13. Global Andexxa for ARD Market, 2016-2026(US$ Mn)
FIG 14. Global Octaplex for ARD Market, (US$ Mn)
FIG 15. U.S. ARD Market, 2016-2026 (US$ Mn)
FIG 16. Canada ARD Market, 2016-2026 (US$ Mn)
FIG 17. U.K. ARD Market, 2016-2026 (US$ Mn)
FIG 18. Germany ARD Market, 2016-2026 (US$ Mn)
FIG 19. Rest of Europe ARD Market, 2016-2026 (US$ Mn)
FIG 20. China ARD Market, 2016-2026 (US$ Mn)
FIG 21. Japan ARD Market, 2016-2026 (US$ Mn)
FIG 22. Rest of Asia Pacific ARD Market, 2016-2026 (US$ Mn)
FIG 23. Brazil ARD Market, 2016-2026 (US$ Mn)
FIG 24. Mexico ARD Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Latin America ARD Market, 2016-2026 (US$ Mn)
FIG 26. GCC ARD Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Middle East & Africa ARD Market, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Anticoagulant Reversal Drugs (ARD) Market Portraiture
TABLE 2 Global ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Phase I and II Drug for ARD Market
TABLE 4 Global ARD Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 North America ARD Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 8 Europe ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East & Africa ARD Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 14 Middle East & Africa ARD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 15 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Fresenius Kabi AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Bausch Health Companies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Amneal Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 CSL Behring Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Octapharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Portola Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Perosphere Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Ferring Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions:

What is the size of Anticoagulant Reversal Drugs Market?

The market for Anticoagulant Reversal Drugs Market is expected to reach US$ XX Bn By 2026.

What is the Anticoagulant Reversal Drugs Market CAGR?

The Anticoagulant Reversal Drugs Market is expected to see significant CAGR growth over the coming years, at 15.3%.

What is the Forecast period considered for Anticoagulant Reversal Drugs Market?

The report is forecasted from 2018-2026.

What is the base year considered for Anticoagulant Reversal Drugs Market?

The base year of this report is 2017.

Who are the major players in this market?

Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc are some of the major players in the global market.

Healthcare

Postoperative Pain Medication Market

Published Date: Oct 2023

Category: Healthcare

Report ID: 62141

Report Format: PDF

No of Pages: 255

HealthCare

Microplate Systems Market

Published Date: Oct. 2023
Category: Medical Devices
Report ID: 62142
Report Format: PDF
No of Pages: 228

Healthcare

Solid Organ Transplant Immunosuppressants Market

Published Date: Oct 2023

Category: Healthcare

Report ID: 62140

Report Format: PDF

No of Pages: 255

 

Healthcare

3D Cell Culture Market

Published Date: Oct 2023
Category: Healthcare
Report ID: 58421
Report Format: PDF
No of Pages: 233

health

Oral Care Market

Published Date: Oct 2023
Category: Healthcare
Report ID: 58117
Report Format: PDF
No of Pages: 190

Healthcare

Healthcare Mobility Solutions Market

Published Date: Oct. 2023
Category: Technology & Media
Report ID: 57752
Report Format: PDF
No of Pages: 236

Healthcare

Autologous Cell Therapy Market

Published Date: Oct 2023
Category: Healthcare
Report ID: 62137
Report Format: PDF
No of Pages: 240

Healthcare

High Grade Neuroendocrine Neoplasms Market

Published Date: Oct. 2023
Category: Healthcare
Report ID: 62130
Report Format: PDF
No of Pages: 222

Healthcare

ELISA Testing Market

Published Date: Oct. 2023
Category: Medical Devices
Report ID: 62139
Report Format: PDF
No of Pages: 247

Healthcare

Orthopedic Implants Market

Published Date: Oct 2023
Category: Healthcare
Report ID: 62136
Report Format: PDF
No of Pages: 231

Healthcare

Hydatid Disease Treatment Market

Published Date: Oct 2023

Category: Healthcare

Report ID: 62135

Report Format: PDF

No of Pages: 231

Healthcare

Clinical Trial Supplies Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62133
Report Format: PDF
No of Pages: 222

Download Sample Report


Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
WhatsApp Now